TY - JOUR
T1 - Spectral domain optical coherence tomography - Ultra-high speed, ultra-high resolution ophthalmic imaging
AU - Chen, TC
AU - Cense, B
AU - Pierce, MC
AU - Nassif, N
AU - Park, BH
AU - Yun, SH
AU - White, BR
AU - Bouma, BE
AU - Tearney, GJ
AU - de Boer, JF
PY - 2005/12
Y1 - 2005/12
N2 - Objective: To introduce a new ophthalmic optical coherence tomography technology that allows unprecedented simultaneous ultra-high speed and ultra-high resolution.Methods: Using a superluminescent diode source, a clinically viable ultra-high speed, ultra-high resolution spectral domain optical coherence tomography system was developed. resolution of 6 pm. Using a different source in a slightly slower configuration, single images consisting of 500 Ascans were acquired in 34 ms, allowing imaging at 29 frames per second at an axial resolution of 3.5 mu m, which is 3 times better than commercially available optical coherence tomography instruments. The amount of energy directed into the eye in both cases, 600 mu W, is less than that of the Stratus OCT3 and is safe for intrabeam viewing for up to 8 hours at the same retinal location.Results: In vivo images of the retina, the optic nerve head, and retinal blood flow were obtained at an ultra-high speed of 34.1 microseconds (ms) per A-scan, which is 73 times faster than commercially available optical coherence tomography instruments. Single images (B-scans) consisting of 1000 A-scans were acquired in 34.1 ms, allowing video rate imaging at 29 frames per second with an axial resolution of 6 pm. Using a different source in a slightly slower configuration, single images consisting of 500 Ascans were acquired in 34 ms, allowing imaging at 29 frames per second at an axial resolution of 3.5 mu m, which is 3 times better than commercially available optical coherence tomography instruments. The amount of energy directed into the eye in both cases, 600 mu W, is less than that of the Stratus OCT3 and is safe for intrabeam viewing for up to 8 hours at the same retinal location.Conclusion: Spectral domain optical coherence tomography technology enables ophthalmic imaging with unprecedented simultaneous ultra-high speed and ultrahigh resolution.
AB - Objective: To introduce a new ophthalmic optical coherence tomography technology that allows unprecedented simultaneous ultra-high speed and ultra-high resolution.Methods: Using a superluminescent diode source, a clinically viable ultra-high speed, ultra-high resolution spectral domain optical coherence tomography system was developed. resolution of 6 pm. Using a different source in a slightly slower configuration, single images consisting of 500 Ascans were acquired in 34 ms, allowing imaging at 29 frames per second at an axial resolution of 3.5 mu m, which is 3 times better than commercially available optical coherence tomography instruments. The amount of energy directed into the eye in both cases, 600 mu W, is less than that of the Stratus OCT3 and is safe for intrabeam viewing for up to 8 hours at the same retinal location.Results: In vivo images of the retina, the optic nerve head, and retinal blood flow were obtained at an ultra-high speed of 34.1 microseconds (ms) per A-scan, which is 73 times faster than commercially available optical coherence tomography instruments. Single images (B-scans) consisting of 1000 A-scans were acquired in 34.1 ms, allowing video rate imaging at 29 frames per second with an axial resolution of 6 pm. Using a different source in a slightly slower configuration, single images consisting of 500 Ascans were acquired in 34 ms, allowing imaging at 29 frames per second at an axial resolution of 3.5 mu m, which is 3 times better than commercially available optical coherence tomography instruments. The amount of energy directed into the eye in both cases, 600 mu W, is less than that of the Stratus OCT3 and is safe for intrabeam viewing for up to 8 hours at the same retinal location.Conclusion: Spectral domain optical coherence tomography technology enables ophthalmic imaging with unprecedented simultaneous ultra-high speed and ultrahigh resolution.
KW - CYSTOID MACULAR EDEMA
KW - NERVE-FIBER LAYER
KW - CENTRAL SEROUS CHORIORETINOPATHY
KW - RETINITIS-PIGMENTOSA
KW - DOPPLER TOMOGRAPHY
KW - ANTERIOR SEGMENT
KW - HIGH MYOPIA
KW - BLOOD-FLOW
KW - THICKNESS
KW - HOLE
U2 - 10.1001/archopht.123.12.1715
DO - 10.1001/archopht.123.12.1715
M3 - Article
SN - 0003-9950
VL - 123
SP - 1715
EP - 1720
JO - Archives of Ophthalmology
JF - Archives of Ophthalmology
IS - 12
ER -